SCHEDULE: Van Herk Investments Adjusts Stake in ProQR Therapeutics

Van Herk Investments B.V. and affiliated entities have updated their Schedule 13D filing, reporting a 10.9% ownership in ProQR Therapeutics N.V. following a recent share issuance.

Summary

• Van Herk Investments B.V. and several affiliated entities (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13D, reporting their beneficial ownership of ProQR Therapeutics N.V. ordinary shares.
• The Reporting Persons collectively own 15,384,250 ordinary shares, representing approximately 10.9% of the Issuer's outstanding ordinary shares as of June 26, 2026.
• This filing (Amendment No. 6) primarily serves to update the ownership percentage due to a change in the total number of outstanding shares, as described in ProQR Therapeutics N.V.'s Prospectus Supplement dated June 25, 2026.
• The structure of beneficial ownership involves a complex web of Dutch entities including Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Van Herk Management Services B.V., Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., and A. van Herk Holding B.V., along with Dutch foundations Stichting Administratiekantoor Penulata and Stichting Administratiekantoor Abchrys, and ultimately Adrianus van Herk.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily serves as a routine update on beneficial ownership following a share issuance, without providing new operational or financial performance data.

Positives

• The Reporting Persons maintain a significant stake of 10.9% in ProQR Therapeutics N.V., indicating continued strategic interest.
• The filing clarifies ownership structure and percentage following a share issuance, providing transparency to the market.

Negatives

• The filing does not contain any information regarding negative financial performance or operational setbacks for ProQR Therapeutics N.V.

Risks

• The primary risk highlighted is the potential for further changes in shareholding or strategic actions by significant investors like Van Herk Investments, which could influence the company's stock price and strategic direction.
• The reliance on a complex corporate structure for ownership could introduce complexities in governance or communication, though no specific issues are detailed in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance from ProQR Therapeutics N.V. itself. It solely pertains to the updated beneficial ownership disclosure by Van Herk Investments and its affiliates.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for understanding significant shifts in beneficial ownership, particularly in the biotechnology sector where substantial stakes can signal strategic intentions or influence corporate actions. The update from Van Herk Investments reflects a common practice of adjusting disclosures following capital events like share issuances.

Stakeholder Impact

• Shareholders: The update provides clarity on significant ownership levels, which can influence market perception and trading activity. The underlying share issuance may dilute existing shareholders' percentage ownership.
• Management of ProQR Therapeutics N.V.: The filing confirms the continued significant interest of a major investor, which could imply support or potential influence on strategic decisions.
• Creditors: No direct impact is indicated, as the filing focuses on equity ownership.

Next Steps

• Monitor future filings from Van Herk Investments and ProQR Therapeutics N.V. for any further changes in ownership or strategic developments.
• Analyze the impact of the recent share issuance on ProQR Therapeutics N.V.'s financial structure and operational capacity.

Key Dates

Keywords

ProQR Therapeutics, Schedule 13D, Van Herk Investments, Beneficial Ownership, Shareholder, SEC Filing, Netherlands, Ordinary Shares, Prospectus Supplement